#esocsm
LightNews LightNews
grouchyoldhippie.bsky.social
Gotta get me one of these...

#cansky #oncsky #oncosky #esocsm #FuckCancer
December 19, 2024 at 1:02 PM
realbowtiedoc.bsky.social
So much excited data shared on Day 1️⃣ of #GI25 from #biomarker 🎯 testing in #esocsm #stcsm to the role of #RT in #esocsm in light 💡 of #ESOPEC. Excited for more great science and discovery on Day 2️⃣!
January 24, 2025 at 9:48 AM
grouchyoldhippie.bsky.social
Let 2025 be the year we find the cure!

#2025CancerCure

Happy New Year To All!

#cansky #oncsky #oncosky #esocsm
January 1, 2025 at 2:39 PM
mtmdphd.bsky.social
EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 meetings.asco.org/abstracts-pr... #NCT04592913 #stcsm #esocsm
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
April 23, 2025 at 7:24 PM
tmprowell.bsky.social
#OncSky #MedSky

Another subcutaneous #ImmunoOnc therapy (nivo) now officially in the toolkit 👇

#melsm #lcsm #kcsm #blcsm #gicsm #stcsm #esocsm

www.fda.gov/drugs/resour...
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injecti
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
www.fda.gov
December 28, 2024 at 3:20 AM
realbowtiedoc.bsky.social
The best in #GIonc trials to look for at #ASCO25. 2⃣ plenary talks that will revolutionize #crcsm and #esocsm #stmcsm. Can't wait to take this best of science into the clinic!

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · May 23
The #ASCO25 #OncoAlertTOP10 Abstracts in GI Oncology
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@realbowtiedoc.bsky.social‬
@arosen380.bsky.social‬
Ping
‪@gillsharlene.bsky.social‬
May 26, 2025 at 9:41 AM
grouchyoldhippie.bsky.social
Also, I now have some semi permanent tattoos in three places on my torso that they will use for precise positioning and alignment on subsequent scans.

#Cansky #oncsky #oncosky #esocsm #ThanksCancer
December 7, 2024 at 1:16 AM
grouchyoldhippie.bsky.social
UPDATE: Just got home from my first chemo and radiation treatments. Chemo pump on the left and radiation beast on the right. No adverse side effects so far. 👍

💉☢️

#cansky #oncsky #oncosky #esocsm
December 18, 2024 at 11:48 PM
grouchyoldhippie.bsky.social
Recently diagnosed with stage 3 cancer of the esophagus. Had my second scan with contrast today. The nurse drilled in three places to insert the IV in my right arm. She finally gave up and called another nurse who hit oil on her first poke.

#Cansky #oncsky #oconsky #esocsm #ThanksCancer
December 7, 2024 at 1:13 AM
grouchyoldhippie.bsky.social
So, I have radiation sessions scheduled on both Christmas Eve AND New Year's Eve. Happy Holidays! #FuckCancer

#cansky #oncsky #oncosky #esocsm
December 13, 2024 at 12:28 PM
grouchyoldhippie.bsky.social
A little overwhelmed with all the appointments and travel coming up.

Radiation and chemo treatments tentatively scheduled to begin on Dec. 18th. I may be glow-in-the-dark for Christmas! LOL

#CanSky #OncoSky #Oncsky #esocsm
December 10, 2024 at 8:21 PM
ascocancer.bsky.social
The draft guideline update, #immunotherapy and targeted therapy for advanced gastroesophageal cancer, is now available for open comment.

Provide your feedback to us by September 24. #esocsm Learn more: brnw.ch/21wVG8d
September 11, 2025 at 4:29 PM
realbowtiedoc.bsky.social
Exciting #GIonc INFINITY ♾ #Ph2 trial

Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR

12m 🚫🔪#survival ~ 64%.

#Ph3 data needed, but organ preservation possible!

🔗: sciencedirect.com/science/arti...
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INF...
In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit…
sciencedirect.com
January 16, 2025 at 7:59 PM
swog.org
Study S2303 is for people who are seeking further treatment for advanced #stomach or #esophageal #cancer. It tests adding an #immunotherapy drug (#nivolumab) to usual treatment. SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #gastriccancer
Study S2303
February 14, 2025 at 5:42 PM
mtmdphd.bsky.social
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options [Mar 30, 2020] Bitzer et al. @ASCO_pubs ow.ly/MuHP30qAEI0 #PrecisionMedicine #ancsm #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm n=96, Apr 2016 - Feb 2018
January 15, 2025 at 3:02 AM
onclive.bsky.social
Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/trastuz...
Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
www.onclive.com
January 24, 2025 at 1:42 AM
swog.org
Enrolling: #PARAMUNE @SWOG S2303 ph 2/3 randomized #clinicaltrial of paclitaxel + ramucirumab w/wo nivolumab in patients w advanced MSS, HER2- #gastric, #GEJ, or #esophageal #adenocarcinoma w PD-L1 CPS ≥ 1.
SWOG.org/clinical-trials/S2303
PI: Anwaar Saeed, MD @upmchillmancc.bsky.social #esocsm #gicsm
S2303 PARAMUNE clinical trial
January 2, 2025 at 3:56 PM
ascocancer.bsky.social
Delving into the❓“Organ Preservation for Gastroesophageal Junction & Gastric Adenocarcinoma: Ready for Primetime?” w co-chairs Drs. Daniel Tandel Chang & Ugwuji Maduekwe @ #GI26. Case-based discussions w/ opposing views. 🔥 #esocsm meetings.asco.org/meetings/202...
January 8, 2026 at 7:06 PM
grouchyoldhippie.bsky.social


I also have to try to schedule physio treatments for the hip rehab. Not sure I can do the physio during the radiation/chemo sessions, so that may have to wait.

#CanSky #OncoSky #OncSky #esocsm
December 10, 2024 at 8:23 PM
onclive.bsky.social
Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/neoadju...
Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC
Neoadjuvant sintilimab plus chemoradiotherapy improved pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.
www.onclive.com
January 24, 2025 at 5:56 PM
swog.org
Do you have #esophageal or #stomach #cancer that has spread or can’t be removed with surgery? If initial treatment didn’t work or stopped working, study S2303 may be an option for you.
SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #PARAMUNE
SWOG S2303 study
December 23, 2024 at 5:15 PM
onclive.bsky.social
Society of Surgical Oncology Highlights Roswell Park Experts at 2025 Annual Meeting @aerynkd.bsky.social @roswellpark.bsky.social @socsurgonc.bsky.social #SSO2025 #esocsm #melsm #bcsm #crcsm #oncology
www.onclive.com/view/society...
Society of Surgical Oncology Highlights Roswell Park Experts at 2025 Annual Meeting
Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.
www.onclive.com
March 25, 2025 at 8:32 PM
onclive.bsky.social
Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma @ascocancer.bsky.social #GI26 #esocsm #oncology
www.onclive.com/view/zanidat...
Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma | OncLive
HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.
www.onclive.com
January 8, 2026 at 11:10 PM
onclive.bsky.social
First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer @mskcancercenter.bsky.social @ascocancer.bsky.social #GI24 #esocsm #oncology
www.onclive.com/view/first-l...
First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
www.onclive.com
January 23, 2025 at 9:20 PM
onclive.bsky.social
Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/camreli...
Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer
Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.
www.onclive.com
January 25, 2025 at 7:48 PM